Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03253211 · ClinicalTrials.gov registry record
Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 4,392
- Enrollment target
NCT03253211: Completed study, sponsored by Duke University.
NCT03253211 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 4,392 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03253211 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 4,392 participants
- Enrollment target
Study Summary
This project will improve the efficiency and quality of healthcare for persons with sickle cell disease, an under-served and at risk population by implementing a co-management model of care. Many patients with sickle cell disease (SCD) receive care primarily from specialty physicians and emergency departments (ED), thus resulting in a lack of primary care and a high number of ED visits and hospitalizations. The goal is to improve PCP and SCD specialist co-management. The overall purpose of this dissemination project is to evaluate utilization data, as well as patient and provider reported outcomes associated with the dissemination of a toolbox of decision support tools to PCP's and ED providers across NC and SC.
Primary Outcome
number of hydroxyurea prescription refills per patient
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,392 participants |
| Start Date | 2018-11-06 |
| Est. Completion | 2019-12-15 |
What the finished NCT03253211 record still lists
NCT03253211 is an observational study that tracks outcomes without assigning an intervention. Its 4,392 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03253211 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03253211 about?
NCT03253211 is a clinical study titled "Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina". This project will improve the efficiency and quality of healthcare for persons with sickle cell disease, an under-served and at risk population by implementing a co-management model of care. Many patients with sickle cell disease (SCD) receive care primarily from specialty physicians and emergency d...
What is the current status of trial NCT03253211?
This trial is currently completed. The enrollment target is 4,392 participants. The study started on 2018-11-06. Estimated completion is 2019-12-15.
Who is sponsoring clinical trial NCT03253211?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07044297 · 4,390 participants · Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
- NCT02660645 · 4,400 participants
Blue Light Cystoscopy With Cysview® Registry
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI